drugset
drugset / Trial / NCT05717686

A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

NCT05717686 ↗

Phase 1 Completed 64 enrolled AusperBio Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses. In addition, the study will evaluate the initial antiviral efficacy of AHB-137 in CHB patients following a multiple dosing regimen.

Timeline

Start
2023-02-28
Primary completion
2025-01-07
Completion
2025-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AHB-137 Antisense oligonucleotide 200 mg Subcutaneous
Subject AHB-137 Antisense oligonucleotide 300 mg Subcutaneous
Subject AHB-137 Antisense oligonucleotide 450 mg Subcutaneous

Indications

chronic hepatitis B virus infection